Dupixent Is Now FDA-Approved for Chronic Hives. Your Insurer May Still Say No.
Dupixent Is Now FDA-Approved for Chronic Hives. Your Insurer May Still Say No.
5 minute read
In April 2025, the FDA approved Dupixent (dupilumab) for chronic spontaneous urticaria, a condition that causes recurring, unpredictable hives that resist standard antihistamine treatment. The approval was the seventh indication for the drug, which had already been approved for atopic dermatitis, asthma, eosinophilic esophagitis, and several other conditions.¹
If you have been living with chronic hives that antibiotics and antihistamines cannot control, this approval is meaningful news. But it does not guarantee that your insurance will cover it. The path from FDA approval to insurer coverage can take months, and in some cases, plans may still deny Dupixent for urticaria even though the FDA has cleared it for that use.
Understanding why that happens, and what you can do about it, is the purpose of this post.
What Is Chronic Spontaneous Urticaria and Who Does It Affect?
Chronic spontaneous urticaria is defined as hives that appear at least twice per week for six weeks or longer, without a clear external trigger. "Spontaneous" distinguishes it from forms of urticaria caused by physical stimuli like pressure, cold, or heat. The condition causes hives, intense itching, swelling, and in some cases angioedema, a deeper swelling of tissues beneath the skin.
Regeneron, Dupixent's manufacturer alongside Sanofi, estimates that more than 300,000 people in the United States have chronic spontaneous urticaria that persists despite antihistamine treatment.¹ For those individuals, the only existing biologic option before this approval was Xolair (omalizumab), which is also on Ellen's list of top specialty drugs and carries its own coverage challenges.
Dupixent received FDA approval for urticaria in patients 12 years of age and older whose symptoms are not adequately controlled by antihistamines. The approval was based on data from the Liberty-Cupid Study C trial, in which patients adding Dupixent to antihistamines experienced nearly a 50% reduction in itch and urticaria activity scores compared to placebo.¹
Why Insurers May Still Deny Coverage
FDA approval establishes that a drug is safe and effective for a condition. It does not require insurers to cover it. Coverage decisions are made by each plan independently, based on their own clinical coverage policies, formulary management, and cost considerations. After a new indication is approved, there is typically a lag period of weeks to several months before plans update their coverage policies to include the new use.
For a drug as expensive as Dupixent, the lag can be intentional. Monthly costs for Dupixent can exceed $3,000 before insurance, and specialty biologics routinely require prior authorization regardless of the indication. Here is what the denial landscape for Dupixent urticaria coverage currently looks like.
Step therapy requirements. Many plans will require that you first try Xolair for urticaria before approving Dupixent. This is a standard fail-first requirement. If you have not been on Xolair, or if Xolair was ineffective or caused intolerance, your physician will need to document that history specifically in the prior authorization submission.
"Not medically necessary" language. Some plans are still using outdated clinical coverage criteria that predate the urticaria indication and will return a denial citing that Dupixent is not covered for the diagnosis code you submitted. If you see this type of denial, it is important to check whether your plan's coverage policy has been updated since April 2025.
Off-label denial misclassification. A small number of plans may initially deny Dupixent for urticaria as an off-label use, even though the FDA approval means it is no longer off-label for this condition. This is a documentable error, and the correct response is a formal appeal citing the FDA approval date and indication language directly.
The Step Therapy Problem for Dupixent
Step therapy, sometimes called fail-first requirements, is the most common barrier patients with chronic hives face when seeking Dupixent coverage. The logic is that Xolair has been the standard biologic for refractory urticaria for years, and it is often less expensive for the plan. Many formularies have therefore positioned Dupixent as a second-line option.
Whether this is appropriate in your situation depends on your clinical history. If Xolair was not tolerable, did not provide adequate relief, or is contraindicated for you, you have the clinical grounds to request a step therapy exception.
As of 2026, 17 states have enacted step therapy reform legislation that limits when insurers can require step therapy under certain conditions.² Generally, these laws provide exceptions when you have already tried and failed the required prior-line medication, when the required medication is clinically contraindicated, or when the condition is likely to worsen significantly during the step therapy period.
Your physician can formally request a step therapy exception as part of the prior authorization process. If the plan denies the exception, that denial is separately appealable.
What to Include in a Dupixent Urticaria Appeal
If your prior authorization or step therapy exception request for Dupixent is denied, a formal written appeal gives you the best opportunity for reconsideration. Here is what the appeal should include.
The FDA approval documentation. The FDA approved Dupixent for chronic spontaneous urticaria on April 18, 2025, specifically for patients 12 and older whose symptoms are inadequately controlled with antihistamines. This approval language should be cited directly in any appeal.¹
Your treatment history. Document every antihistamine and biologic you have tried, with dates, doses, and why each was discontinued or deemed inadequate. If you tried Xolair, include the duration, dose, and response. If you did not try Xolair because it is contraindicated (for example, due to a latex allergy or prior hypersensitivity reaction), include that documentation.
Your current symptom severity. Your physician should document how your symptoms affect daily functioning, sleep, and quality of life. Objective measures like the Urticaria Activity Score can help standardize this documentation.
A peer-to-peer request. If the written appeal is denied, ask your physician to request a peer-to-peer conversation with the insurer's medical reviewer. Peer-to-peer reviews are frequently the step that tips a denial toward approval, particularly when the prescribing physician can directly address the clinical criteria the reviewer is applying.
Frequently Asked Questions
How long has Dupixent been FDA-approved for chronic hives?
The FDA approved Dupixent for chronic spontaneous urticaria on April 18, 2025.¹ It is approved for patients aged 12 and older whose symptoms persist despite antihistamine treatment.
My insurer says Dupixent is not covered for hives. Is that legal?
Insurers are not required to cover every FDA-approved drug for every indication. However, if your plan covers Dupixent for other conditions, a complete exclusion for the urticaria indication may be challengeable, particularly if it conflicts with updated coverage criteria. Filing a formal appeal is the first step.
Does Xolair also treat chronic hives?
Yes. Xolair (omalizumab) is FDA-approved for chronic idiopathic urticaria in adults and adolescents 12 and older. If you have not tried Xolair, many plans will require it before approving Dupixent. If Xolair failed or is not appropriate for you, document that history carefully.
What is the difference between Dupixent and Xolair for hives?
Both are injectable biologics. Xolair targets a different pathway (IgE) and is administered monthly. Dupixent targets the IL-4 and IL-13 pathways associated with type 2 inflammation. Neither is universally more effective; the right choice depends on individual patient factors and response. Your physician is the right person to make that determination for your specific case.
If your plan has denied Dupixent for chronic hives, Ellen can help you understand the denial reason, find the coverage criteria your insurer is applying, and draft an appeal that addresses those criteria directly. Start here.
Sources: